CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Reform Pharma Plc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Reform Pharma Plc
Lg Floor 31 St James Square
Norfolk House
Phone: +44 2074512468p:+44 2074512468 LONDON, SW1Y 4JR  United Kingdom Ticker: REPPREPP
Business Summary
Reform Pharma Plc, formerly Accura Pharma Plc, is a biopharmaceutical company that in-licenses early stage pharmaceutical therapeutics from academia, small biotech and large pharmaceutical companies and develops those products utilizing contracted resources to do so, then commercializes the products until they become targets and are acquired by pharmaceutical companies that have a marketing and sales focus. As of April 30, 2006, 15 products had been in-licensed to the Company or terms had been agreed, of which two products are under a structured development program. The Company operates through its wholly owned subsidiary, Accura Therapeutics Limited. Accura Therapeutics develops products for cardiovascular, oncology and lifestyle drugs. In December 2005, Accura Therapeutics acquired Anvet Pharma Limited will develop products in animal health specifically for companion animals. In March 2006, it Accura Therapeutics acquired Cain Biotech Limited.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-------

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
4/30/20094/30/2006Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer, Director Kevin G.Bilyard 50
Chief Financial Officer, Director Robert J.Barker 47 3/29/2006
Non-Executive Director Bernard J.Ross 43 3/29/2006 3/29/2006
Non-Executive Director CamiloColaco 51

Business Names
Business Name
Accura Pharma Plc
REPP

General Information
Outstanding Shares: 114,902,911 (As of 10/31/2008)
Stock Exchange: OFEX
Fax Number: +44 2074512469


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, August 30, 2023